Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 405

1.

Caspase activity modulators as anticancer agents.

Okun I, Balakin KV, Tkachenko SE, Ivachtchenko AV.

Anticancer Agents Med Chem. 2008 Apr;8(3):322-41. Review.

PMID:
18393791
2.

Staurosporine and conventional anticancer drugs induce overlapping, yet distinct pathways of apoptosis and caspase activation.

Stepczynska A, Lauber K, Engels IH, Janssen O, Kabelitz D, Wesselborg S, Schulze-Osthoff K.

Oncogene. 2001 Mar 8;20(10):1193-202.

3.

The role of caspase-8 in resistance to cancer chemotherapy.

Kim PK, Mahidhara R, Seol DW.

Drug Resist Updat. 2001 Oct;4(5):293-6. Review.

PMID:
11991682
4.

Therapeutic potential of AIF-mediated caspase-independent programmed cell death.

Lorenzo HK, Susin SA.

Drug Resist Updat. 2007 Dec;10(6):235-55. doi: 10.1016/j.drup.2007.11.001. Epub 2008 Jan 3. Review.

PMID:
18180198
5.
6.

Therapeutic activation of caspases in cancer: a question of selectivity.

Beauparlant P, Shore GC.

Curr Opin Drug Discov Devel. 2003 Mar;6(2):179-87. Review.

PMID:
12669453
7.

Caspase-independent pathways of programmed cell death: the unraveling of new targets of cancer therapy?

Constantinou C, Papas KA, Constantinou AI.

Curr Cancer Drug Targets. 2009 Sep;9(6):717-28. Review.

PMID:
19754356
8.

Caspases: potential targets for regulating cell death.

Philchenkov A.

J Cell Mol Med. 2004 Oct-Dec;8(4):432-44. Review.

9.

Role of caspases in apoptosis and disease.

Khanna N, Singh N.

Indian J Physiol Pharmacol. 1999 Apr;43(2):151-9. Review.

PMID:
10365305
10.

Cellular stress response and apoptosis in cancer therapy.

Herr I, Debatin KM.

Blood. 2001 Nov 1;98(9):2603-14. Review.

11.
12.

Changes in the apoptotic and survival signaling in cancer cells and their potential therapeutic implications.

Kabore AF, Johnston JB, Gibson SB.

Curr Cancer Drug Targets. 2004 Mar;4(2):147-63. Review.

PMID:
15032666
13.

Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment.

Rodriguez-Nieto S, Zhivotovsky B.

Curr Pharm Des. 2006;12(34):4411-25. Review.

PMID:
17168751
14.

Caspase inhibitors in prevention of apoptosis.

Rudel T.

Herz. 1999 May;24(3):236-41. Review.

PMID:
10412648
15.

Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy.

Putt KS, Chen GW, Pearson JM, Sandhorst JS, Hoagland MS, Kwon JT, Hwang SK, Jin H, Churchwell MI, Cho MH, Doerge DR, Helferich WG, Hergenrother PJ.

Nat Chem Biol. 2006 Oct;2(10):543-50. Epub 2006 Aug 27.

PMID:
16936720
16.

Cell death independent of caspases: a review.

Bröker LE, Kruyt FA, Giaccone G.

Clin Cancer Res. 2005 May 1;11(9):3155-62. Review.

17.

Effect of the polyamine analogue N1,N11-diethylnorspermine on cell survival and susceptibility to apoptosis of human chondrocytes.

Stanic I, Cetrullo S, Facchini A, Stefanelli C, Borzì RM, Tantini B, Guarnieri C, Caldarera CM, Flamigni F.

J Cell Physiol. 2008 Jul;216(1):153-61. doi: 10.1002/jcp.21387.

PMID:
18231987
18.

[Antimitochondrial agents: a new class of anticancer agents].

André N, Rome A, Carré M; Société Francophone de Recherche en Pédiatrie (SFRP).

Arch Pediatr. 2006 Jan;13(1):69-75. Epub 2005 Nov 16. Review. French.

PMID:
16298120
19.

Anti-apoptotic gene therapy in Parkinson's disease.

Schulz JB.

J Neural Transm Suppl. 2006;(70):467-76. Review.

PMID:
17017569
20.

Farnesyltransferase inhibitors as anticancer agents: current status.

Zhu K, Hamilton AD, Sebti SM.

Curr Opin Investig Drugs. 2003 Dec;4(12):1428-35. Review.

PMID:
14763128

Supplemental Content

Support Center